Mobile

A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects with Relapsed Chronic Lymphocytic Leukemia (COMPL...

Update Il y a 5 ans
Reference: EUCTR2008-005811-16

A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects with Relapsed Chronic Lymphocytic Leukemia (COMPLEMENT 2 STUDY)

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective is to evaluate progression free survival of combination ofatumumab-fludarabine-cyclophosphamide therapy vs. fludarabine-cyclophosphamide therapy for the treatment of relapsed CLL.

Inclusion criteria

  • Chronic Lymphocytic Leukaemia

Links